Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase 3 1Phase 1/2 1

Status

Completed 16Terminated 3Active not recruiting 3Withdrawn 2Unknown 2

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1Breast 1

Conditions

Melanoma 1Chondrosarcoma, Mesenchymal 1Chondrosarcoma, Clear Cell 1Chondrosarcoma 1Breast Neoplasms 1

Interventions

pembrolizumab 195Nivolumab 146Carboplatin 134Specimen Handling 130Magnetic Resonance Spectroscopy 115Cyclophosphamide 109Paclitaxel 106Cisplatin 98Biopsy 97Radiotherapy 90durvalumab 81Dexamethasone 79atezolizumab 73Ipilimumab 62Gemcitabine 62Rituximab 59Doxorubicin 59Lenalidomide 55Docetaxel 55olaparib 52Bevacizumab 51Capecitabine 50Fluorouracil 49Etoposide 49Radiation 47Oxaliplatin 47Radiosurgery 42Prednisone 42venetoclax 41Taxes 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Active not recruiting × Pharmacogenomic Testing × Clear all
NCT02581930 2026-04-30

Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma

National Cancer Institute (NCI)

Phase 2 Active not recruiting
18 enrolled 10 charts
Dermatologic

Melanoma

NCT01267955 2026-04-13

Vismodegib in Treating Patients With Advanced Chondrosarcomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
45 enrolled 10 charts
Sarcoma

Chondrosarcoma, Clear Cell, Chondrosarcoma, Chondrosarcoma, Mesenchymal

NCT01196936 2026-01-05

LDTam

University of Alabama at Birmingham

Phase 2 Active not recruiting
84 enrolled 17 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡